Patents by Inventor Sandra Berndt
Sandra Berndt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240043379Abstract: The invention relates to novel prodrugs or conjugates of the general formula (Ia) in which cytotoxic drugs, for example kinesin spindle protein inhibitors, are masked with legumain-cleavable groups and hence release the drug, and to the use of these prodrugs or conjugates for treatment and/or prevention of diseases, and to the use of these prodrugs or conjugates for production of medicaments for treatment and/or prevention of diseases, especially of hyperproliferative and/or angiogenic disorders, for example cancers.Type: ApplicationFiled: February 27, 2023Publication date: February 8, 2024Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Leo MARX, Sarah Anna Liesa JOHANNES, Beatrix STELTE-LUDWIG, Lisa DIETZ, Carsten TERJUNG, Christoph MAHLERT, Simone GREVEN, Anette SOMMER, Sandra BERNDT
-
Publication number: 20230338559Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.Type: ApplicationFiled: March 10, 2023Publication date: October 26, 2023Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Lisa DIETZ, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Sandra BERNDT, Anette SOMMER, Stefanie HAMMER
-
Publication number: 20230250178Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: ApplicationFiled: June 25, 2021Publication date: August 10, 2023Inventors: Sandra BERNDT, Katharina FILARSKY, Philipp ELLINGER, Beatrix STELTE-LUDWIG, Sabine HOFF, Helge ROIDER, Ernst WEBER, Mark TRAUTWEIN, Christian VOTSMEIER, Nikolaus PAWLOWSKI, Uwe GRITZAN, Pascale BUCHMANN, Christian BERTLING, Oliver VON AHSEN, Wiebke Maria NADLER, Su-Yi TSENG, Pedro PAZ, Phaik Lyn OH, Patrick JONES, Matyas GORJANACZ
-
Patent number: 11685714Abstract: The invention relates to novel prodrugs or conjugates of the general formula (Ia) in which cytotoxic drugs, for example kinesin spindle protein inhibitors, are masked with legumain-cleavable groups and hence release the drug, and to the use of these prodrugs or conjugates for treatment and/or prevention of diseases, and to the use of these prodrugs or conjugates for production of medicaments for treatment and/or prevention of diseases, especially of hyperproliferative and/or angiogenic disorders, for example cancers.Type: GrantFiled: March 21, 2017Date of Patent: June 27, 2023Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Leo Marx, Sarah Anna Liesa Johannes, Beatrix Stelte-Ludwig, Lisa Dietz, Carsten Terjung, Christoph Mahlert, Simone Greven, Anette Sommer, Sandra Berndt
-
Patent number: 11660351Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.Type: GrantFiled: December 14, 2017Date of Patent: May 30, 2023Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Beatrix Stelte-Ludwig, Dennis Kirchhoff, Lisa Dietz, Christoph Mahlert, Simone Greven, Stephan Märsch, Sandra Berndt, Anette Sommer, Stefanie Hammer
-
Publication number: 20230039341Abstract: The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.Type: ApplicationFiled: July 13, 2021Publication date: February 9, 2023Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Leo MARX, Beatrix STELTE-LUDWIG, Carsten TERJUNG, Christoph MAHLERT, Simone GREVEN, Anette SOMMER, Sandra BERNDT
-
Publication number: 20220363768Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: ApplicationFiled: April 22, 2022Publication date: November 17, 2022Inventors: Sandra Berndt, Katharina Filarsky, Sabine Hoff, Helge Roider, Uwe Gritzan, Christian Votsmeier, Wiebke Maria Nadler, Su-Yi Tseng
-
Publication number: 20220362392Abstract: Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.Type: ApplicationFiled: July 12, 2022Publication date: November 17, 2022Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Sandra BERNDT, Lisa DIETZ, Stephan MÄRSCH, Stefanie HAMMER
-
Patent number: 11478554Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.Type: GrantFiled: September 1, 2021Date of Patent: October 25, 2022Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Beatrix Stelte-Ludwig, Dennis Kirchhoff, Lisa Dietz, Christoph Mahlert, Simone Greven, Stephan Märsch, Sandra Berndt, Anette Sommer, Stefanie Hammer
-
Patent number: 11433140Abstract: Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.Type: GrantFiled: December 18, 2017Date of Patent: September 6, 2022Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Beatrix Stelte-Ludwig, Dennis Kirchhoff, Sandra Berndt, Lisa Dietz, Stephan Märsch, Stefanie Hammer
-
Patent number: 11427578Abstract: The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I), in which A, X, R1, R2a, R2b, R3a, R3b, R4a and R4b are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients.Type: GrantFiled: July 12, 2018Date of Patent: August 30, 2022Assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Jeffrey Stuart Mowat, Bernd Buchmann, Nuria Aiguabella Font, Gabriele Leder, Rafael Carretero, Olaf Panknin, Roland Neuhaus, Robin Michael Meier, Sandra Berndt, Kirstin Petersen, Rienk Offringa
-
Patent number: 11427640Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: GrantFiled: June 25, 2021Date of Patent: August 30, 2022Assignee: BAYER AKTIENGESELLSCHAFTInventors: Sandra Berndt, Katharina Filarsky, Sabine Hoff, Helge Roider, Uwe Gritzan, Christian Votsmeier, Wiebke Maria Nadler, Su-Yi Tseng
-
Publication number: 20220047603Abstract: The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I) in which A, X, R1a, R1b, R2, R3a, R3b, R4a and R4b are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 4, 2019Publication date: February 17, 2022Applicants: BAYER AKTIENGESELLSCHAFT, DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Jeffrey Stuart MOWAT, Bernd BUCHMANN, Nuria AIGUABELLA FONT, Roland NEUHAUS, Gabriele LEDER, Rafael CARRETERO, Sandra BERNDT, Rienk OFFRINGA
-
Publication number: 20220016258Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.Type: ApplicationFiled: September 1, 2021Publication date: January 20, 2022Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Lisa DIETZ, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Sandra BERNDT, Anette SOMMER, Stefanie HAMMER
-
Patent number: 11123439Abstract: The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.Type: GrantFiled: June 20, 2016Date of Patent: September 21, 2021Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Leo Marx, Beatrix Stelte-Ludwig, Carsten Terjung, Christoph Mahlert, Simone Greven, Anette Sommer, Sandra Berndt
-
Patent number: 11071788Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: June 20, 2016Date of Patent: July 27, 2021Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Sandra Berndt, Uwe Gritzan, Jenny Fitting, Beatrix Stelte-Ludwig, Patrick Jones, Christoph Mahlert, Christian Votsmeier, Dorian Schönfeld, Mark Trautwein, Ernst Weber, Nikolaus Pawlowski, Simone Greven, Julian Marius Glück, Stefanie Hammer, Lisa Dietz, Stephan Märsch
-
Publication number: 20200138970Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: June 20, 2016Publication date: May 7, 2020Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Sandra BERNDT, Uwe GRITZAN, Jenny FITTING, Beatrix STELTE-LUDWIG, Patrick JONES, Christoph MAHLERT, Christian VOTSMEIER, Dorian SCHÖNFELD, Mark TRAUTWEIN, Ernst WEBER, Nikolaus PAWLOWSKI, Simone GREVEN, Julian Marius GLÜCK, Stefanie HAMMER, Lisa DIETZ, Stephan MÄRSCH
-
Publication number: 20190365916Abstract: Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.Type: ApplicationFiled: December 18, 2017Publication date: December 5, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Sandra BERNDT, Lisa DIETZ, Stephan MÄRSCH, Stefanie HAMMER
-
Patent number: 10485880Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: December 10, 2015Date of Patent: November 26, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Hans-Georg Lerchen, Sven Wittrock, Yolanda Cancho Grande, Beatrix Stelte-Ludwig, Anette Sommer, Sandra Berndt, Christoph Mahlert, Anne-Sophie Rebstock, Carsten Terjung, Simone Greven
-
Publication number: 20190328897Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.Type: ApplicationFiled: December 14, 2017Publication date: October 31, 2019Applicants: Bayer Pharma Aktiengesellschaft, Bayer AktiengesellschaftInventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Lisa DIETZ, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Sandra BERNDT, Anette SOMMER, Stefanie HAMMER